Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
14 nov. 2024 16h10 HE
|
Fortress Biotech, Inc.
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally...
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
04 nov. 2024 07h00 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and...
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
15 oct. 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies...
Inbiome, developing a new PCR technology capable of simultaneous identification of hundreds of bacterial pathogens in a single test, welcomes Professor Dr. Carl Wittwer to its Advisory Board
20 sept. 2024 05h03 HE
|
inbiome
Amsterdam, The Netherlands, September 20, 2024. Inbiome, a pioneer in advanced molecular diagnostics, today announced the appointment of Professor Dr. Carl Wittwer (picture), a global authority in PCR...
Philips announces FDA approval for enhanced LumiGuide guidewire and marks the 1000th patient treated with its breakthrough 3D device guidance technology
17 sept. 2024 08h56 HE
|
Royal Philips
Enhanced longer version of Philips LumiGuide Navigation Wire enables US clinicians to visualize a broader range of catheters Internationally recognized vascular surgeon Carlos Timaran, MD, was the...
Bispecific Antibody Drug Conjugates Clinical Trials Insight
17 sept. 2024 07h14 HE
|
KuicK Research
Delhi, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The global market for bispecific antibody-drug conjugates (BsADCs) has experienced remarkable expansion, attributed to their revolutionary capabilities in...
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
12 sept. 2024 08h30 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
05 sept. 2024 17h34 HE
|
Travere Therapeutics, Inc.
Travere Therapeutics announced that the U.S. FDA has granted full approval to FILSPARI® (sparsentan) to treat IgA nephropathy.
Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved
13 août 2024 07h45 HE
|
Cingulate Inc.
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 targeted in 1H 2025Licensing Activity Continues KANSAS CITY, Kan., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a...
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
18 juil. 2024 08h00 HE
|
Phathom Pharmaceuticals
VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD)